Biopharmaceutical firm Eikon Therapeutics files for US IPO
ReutersJan 9, 2026 9:08 PM
Jan 9 (Reuters) - Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Venezuela Oil Exports Use USDT Heavily, Is Bitcoin Dominance at Risk?
Maduro's aggressive adoption of Tether for oil settlements has fueled a surge in USDT's market capitalization. Will this trend drive its market cap to surpass that of Bitcoin?TradingKey
2 hours ago
Tesla 2026: Deep Tech Breakthroughs Finally Move the Needle on Earnings
If 2025 was a turbulent year for Tesla, characterized by speculative valuation promises, then with the realization of commercial commitments such as the mass production of Cybercab and Optimus, 2026 could be a year for Tesla to consolidate its technological advancements and return to fundamentals.TradingKey
Thu, Jan 8
Dogecoin Price Prediction: 2025 Maximum Drawdown Over 70%, 2026 DOGE Will Hit $1 Mark?
Overall, Dogecoin's future remains highly uncertain. While it showed strong rebound momentum in early 2026, its price gains primarily depend on community consensus and market sentiment due to a lack of technical and ecosystem support. Should Bitcoin reach new highs again, DOGE might follow suit. HowTradingKey
Tue, Jan 6
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
